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This paper reviews the available data on the prevalence of thrombophilia defects in patients with peripheral vascular disease
(PVD) and attempts to delineate the risk of failure of vascular intervention in these patients. The prevalence of thrombophilia
in stable claudicants is 25% and increases to 40% in those requiring revascularisation, compared to only 11% in the control
group. The overall prevalence of thrombophilia defects in patients with premature atherosclerosis appears to be between 15
and 30%. The prevalence in the typical cohort of patients with PVD appears to be similar. All these studies have recruited
patients with symptoms significant enough to warrant intervention. The overall prevalence of thrombophilia calculated from
these trials, therefore, may not be truly indicative of the general vascular population who may not even present primary or
secondary healthcare. The risk of thrombotic occlusion following arterial revascularisation in patients with an identified
thrombophilia defect appears to be almost three times that of patients with no evidence of a thrombophilia defect. The best
management of these patients has not been determined and needs to be evaluated by prospective randomized trials.
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Introduction
There are few studies recording the prevalence of
thrombophilia defects in patients with vascular dis-
ease, which makes it difficult to calculate the overall
prevalence of thrombophilia defects in these patients.
In addition, the variety of tests used to determine
thrombophilia defects makes comparison of different
series difficult. This paper reviews the available data
on the prevalence of thrombophilia defects in patients
with peripheral vascular disease (PVD) and attempts
to delineate the risk of failure of vascular intervention
in these patients. Individual thrombophilia defects are
not discussed in detail as they have recently been
reviewed by Burns et al.1–5 (Table 1). It does not
include a review of the risk of homocysteine in
patients with PVD as this was also covered in detail
by the review by O’Grady et al.6
Methods
A Medline search was undertaken for English
language articles on thrombophilia, hypercoagulability
and vascular disease. The same search was also
undertaken for arterial and peripheral arterial occlu-
sive disease. In addition each individual thrombo-
philia defect was also searched using the same
strategy. Cross-referencing from the reference lists of
relevant major articles identified further papers
included in this review.
Prevalence of Thrombophilia Defects in Vascular
Patients
There is a higher prevalence of thrombophilia defects
in patients with vascular disease compared to the
general population. The prevalence of thrombophilia
in stable claudicants is 25% and increases to 40% in
those requiring revascularisation, compared to only
11% in the control group.7
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Young patients
There have only been four studies detailing patients
with symptoms of lower limb arterial disease who
presented at a young age (age ,50) (Table 2). The
overall prevalence of thrombophilia defects in patients
with premature atherosclerosis appears to be between
15 and 30%.8–11 Valentine et al. showed that the
prevalence of thrombophilia defects was 15%, twice
that of age matched controls.8 Levy et al.‘s study used a
comprehensive thrombophilia screen but data are not
available to calculate how many patients had multiple
defects and, therefore, the overall percentage of these
defects.11 Eldrup-Jorgensen et al.‘s study used a
limited thrombophilia screen (Antiphospholipid syn-
drome, Protein C and S deficiencies) and reported a
prevalence twice that of Valentine et al.‘s study but the
same as Aronsen et al. at 30%.9,10 Aronsen et al.‘s study
again only used a limited thrombophilia screen
(Protein S, C and Antithrombin deficiencies as well
as assays for Von Willebrand factor and Factor VIII).10
The true prevalence cannot be calculated, as there is
difficulty in obtaining a comprehensive screening test
for thrombophilia, however, the data summarised in
Table 2 suggests an overall prevalence of 30%, but this
may well be higher.
Elderly patients
The prevalence of thrombophilia in vascular surgical
practice, i.e. elderly patients with PVD is also difficult
to elicit. Studies reporting thrombophilia defects in
patients with generalised vascular disease are sum-
marised in Table 3.
Flinn et al. tested for Antithrombin deficiency in
patients undergoing procedures varying from aortic
aneurysm repair, carotid endarterectomy to femoro-
distal bypasses and reported a prevalence of 16.2%.12
Donaldson et al.‘s study used a more comprehensive
thrombophilia screen (Antithrombin, Protein C and S
and lupus anticoagulant) and reported a prevalence of
9.5%. Again the patient group was heterogeneous and
included patients with aneurysmal, renovascular,
cerebrovascular, aorto-iliac and PVD.13
Eason et al.‘s study retrospectively identified 12
patients with a hypercoagulable state in a four-year
period but did not comment on howmany were tested
overall and therefore the prevalence cannot be
calculated.14 Taylor et al. studied a heterogeneous
vascular group and reported a prevalence of 27% with
the most common abnormality detected being Anti-
phospholipid syndrome (26%) (Anticardiolipin and
lupus anticoagulant). This study does not comment on
the incidence of thrombophilia in the different
cohorts.15 Ouriel et al.‘s study only tested for activated
Protein C resistance (carotid disease, aortic aneurysms,
venous thrombotic disease and lower extremity PVD)
and reported a prevalence of 11.6%.16
Sampram et al.‘s study again only tested for a single
thrombophilia defect (Factor V mutation) and
reported a prevalence of 16%.17
Only three studies have looked at a typical cohort of
patients with PVD. Ray et al. recruited patients
attending a vascular clinic with symptoms consistent
with lower limb arterial disease.7 This study reported
a prevalence of thrombophilia of 35% based on a
comprehensive thrombophilia screen but without
testing for Activated Protein C resistance. Lee et al.
reported a 32% prevalence of the Antiphospholipid
Table 1. Thrombophilia defects
Thrombophilia defect
Anti thrombin deficiency Vitamin K dependent irreversible inhibitor of factors XIIa, XIa, Xa and thrombin.
Autosomal dominant trait. Prevalence in the general population is 0.02–0.05%2
Protein C deficiency Vitamin K dependent membrane bound inhibitor of the clotting cascade.
Activated by thrombin bound to thrombomodulin requiring Protein S to inactivate
factors Va and VIIIa inhibiting generation of thrombin and factor Xa. Autosomal
dominant trait. Prevalence in the general population is 0.02%2
Activated Protein C resistance (Factor V Leiden) A single point mutation in the gene for Factor V (factor V Leiden) leads to
resistance to activated Protein C (APCR).3 Prevalence in the general population is
5%4
Protein S deficiency Vitamin K dependent inactivator of factors Va and VIIIa and acts as a cofactor for
Protein C. Autosomal dominant trait
Prothrombin mutation Prothrombin is the precursor of thrombin. This genetic variant involves a
G! A20210 mutation in the prothrombin gene. Prevalence in the general
population is 1%5
The Antiphospholipid syndrome Lupus anticoagulant Presence of immunoglobulins directed at negatively charged phospholipids such
as cardiolipin (anticardiolipin antibody) and the lupus anticoagulant. Lupus
anticoagulant has no inherent anticoagulant property but interferes with the
phospholipid dependent coagulation tests. May act by inhibition of prostacycline
production and Protein C activation.
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Table 2. Prevalence of thrombophilia defects in vascular patients aged <50
Study Patients Thrombophilia screen
Age Overall percentage of
thrombophilia (%)
Anti phospholipid
syndrome
Low
Protein C
Low
Protein S
Low
Antithrombin
APCR (FactorV
Leiden)
Platelet
function
Lower limb ischaemia only
Eldrup Jorgensen et al.
19899
Aged 23–50 30 15% (3/20) 15% (3/20) 20% (4/20) NT* NT* 47% (8/17)
Aronsen et al. 198910 Aged ,45 ,30 NT* 0% (0/37) 8% (3/37) 2.7% (1/37) NT* NT*
Valentine et al. 19968 Aged ,45
Caucasian
15 26% (13/50) 13.3% 0% 2% (1/50) NT* NT*
Levy et al. 199611 Aged ,45 ,30 19.6% (10/51) 15.6%
(8/51)
7.8%
(4/51)
9.8% (5/51) NT*
*NT, not tested.
Table 3. Prevalence of thrombophilia defects in patients with generalised vascular disease aged over 40
Study Patients Thrombophilia screen
Group Overall percentage
(%)
Anti phospholipid
syndrome
Low Prot C Low Prot S Low anti
thrombin
APCR (V) Platelet
function
Mixed vascular pathology
Flinn et al. 198412 Mean age 69 16.4 NT* NT* NT* 16.4% NT* NT*
Donaldson et al.
199013
Mean age 65.4 9.5 3.2% (5/158) 2.5%
(4/158)
0.6% (1/158) 1.2% (2/158) NT* 2.5% (4/158)
Eason et al. 199214 Aged 41–62 NT* 16.7%
(2/12)
25% (3/12) NT* NT* 16.7% (2/12)
Taylor et al. 199415 Mean age 64.6 27 26% (60/234) 0.4%
(1/239)
1.2% (3/239) 0.4% (1/239) NT* NT*
Ouriel et al. 199616 Vascular
outpatients
11.6 NT* NT* NT* NT* 11.6%
(20/173)
NT*
Sampram et al. 200117 12 NT* NT* NT* NT* 12% (93/775) NT*
Lower limb ischaemia only
Ray et al. 19947 Mean age 67 35 15% (9/60) 5% (3/54) 18.5%
(10/54)
1.7% (1/60) NT* NT*
Lee et al. 199618 32 32% (83/262) NT* NT* NT* NT* NT*
Evans et al. 199919 Median age 65 21 13% (15/116) 1.7%
(2/116)
1.7% (2/116) 0.8% (1/116) 2.6% (3/116) NT*
*NT, not tested.
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syndrome.18 The Edinburgh study recruited 116
patients with intermittent claudication with a median
age of 65 and reported a prevalence of 21%.19
All these studies used a variety of criteria to
determine thrombophilia. The true prevalence of
thrombophilia is difficult to determine based on
these limited data. It is more than likely that 25–35%
of patients admitted with vascular disease have
thrombophilia defects that are unrecognised. If hyper-
coagulability encompasses patients with known
defects and other so far undetermined causes then
the overall prevalence maybe much higher.
The most common thrombophilia defect tested was
the Antiphospholipid syndrome that may be present
in over quarter of the vascular population. Other
thrombophilia defects detected in decreasing order of
frequency were:
1. Protein S (0.6–25%).
2. Protein C (0–16.7%).
3. Activated Protein C Resistance/Factor V Leiden
(2.6–12%).
4. Antithrombin deficiency (0.8–16.4%).
Data relating to prevalence of thrombophilia deter-
mined by the type of vascular disease are limited.
Ouriel demonstrated that the frequency of APC
resistance was highest in a group with lower extremity
vascular disease (14%) compared to patients with
abdominal aortic aneurysms (12%) and 9% in patients
with venous thrombosis.16 Patients with carotid artery
disease had the lowest frequency at 5% (Table 4).
Sampram also showed an increase in prevalence of
Factor V Leiden in patients presenting with carotid
disease (9%), aneurysmal disease (14%) and PVD
(16%).17
It has been assumed that a thrombophilia defect
would affect the whole vascular tree presumably to the
same degree. However, it is possible that thrombo-
philia defects are more prevalent in aggressive disease
or lead to severe disease. Lam et al. prospectively
monitored progression of lower limb occlusive disease
following revascularisation.20 Patients with evidence
of the Antiphospholipid syndrome showed no differ-
ence in progression of disease in proximal external
iliac or common femoral arteries. However, there was
significantly increased progression in superficial
femoral and more distal vessels. Multivariate analysis
also confirmed a significant independent association
between APS and progression of disease.
All these studies have recruited patients with
symptoms significant enough to warrant intervention.
The overall prevalence of thrombophilia calculated
from these trials, therefore, may not be truly indicative
of the general vascular population who may not even
present primary or secondary healthcare.
Thrombophilia and Vascular Risk
Several studies have shown that the Antiphospholipid
syndrome is associated with thrombotic events in
coronary arterial disease and cerebrovascular dis-
ease.21–24 Conversely, other studies have reported no
significant association between thrombophilia and
coronary artery disease (CAD). Gorog et al. reported
the coagulation status of 761 patients with CAD
awaiting surgery compared to 100 controls. This
study reported no difference in the coagulation status
of the two groups but showed that platelet reactivity
was significantly increased in patients with severe CAD
compared to patients with single vessel disease.25
Ray et al. demonstrated that only a quarter of stable
claudicants had evidence of thrombophilia but that the
frequency increased to 40% in those patients requiring
vascular intervention.7 Whether patients with PVD
and thrombophilia have an increased risk of pro-
gression to severe disease is unknown, although this
maybe suggested by the higher prevalence of
thrombophilia in patients with severe symptomatic
disease requiring intervention compared to those with
stable claudication. Levy et al. recruited 51 young
patients with lower limb atherosclerotic disease, 47
Table 4. Prevalence of thrombophilia defects in regional vascular disease
Study Patients Presenting vascular abnormality
Group Overall percentage
(%)
Carotid disease
(%)
Aneurysmal disease
(%)
Peripheral arterial
(%)
Venous
(%)
Mixed vascular pathology
Ouriel et al. 199616 Vascular outpatients 11.6 5 12 14 9
Flinn et al. 198412 Mean age 69 16.4 13.3 18.5 16.2 NT*
Sampram et al. 200117 12 9 14 16 21
Lower limb ischaemia only
Ray et al. 19947 Mean age 67 35 NT* NT* 35 NT*
*NT, not tested.
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claudicants, 29 had rest pain and 16 evidence of tissue
loss. The study showed that thrombophilia (especially
a Protein C deficiency) was strongly associated with
acute ischaemia ðp , 0:01Þ; prior vascular intervention
ðp , 0:01Þ and major amputation ðp , 0:01Þ: The data
suggested that thrombophilia played an important
role in early ischaemia and the poor results reported
for lower extremity vascular procedures in patients
with premature atherosclerosis.11
Thrombophilia and Failure of Intervention
Thrombophilia appeared to be associated with high
failure rates of surgical revascularisation procedures
and the data are summarised in Table 5.
Collins et al. reported that patients with markers of
hypercoagulability were six times more likely to
develop complications than controls (10/13 compared
to 2/13).26 Flinn et al. demonstrated that distal
bypasses failed in 33% (5/15) of patients with Anti-
thrombin deficiency compared with 13.4% (9/67) of
controls.12
Donaldson et al.‘s prospective study reported that
9% (5/56) of infrainguinal reconstructions developed
thrombotic graft occlusions (30 days). These occurred
in 50% (3/6) of patients with a thrombophilia defect
compared with only 4% (2/50) of the ‘normal’ group.
Graft failure was, therefore, over 12 times more
common in patients with a known thrombophilia
defect.13 Elrup-Jorgenson et al. carried out a prospec-
tive study of 20 patients below 51 years of age
undergoing intervention vascular patients over a 20-
month period. Of these, only four had no identifiable
thrombophilia defect or platelet problem. Four
patients developed thrombotic complications within
30 days. All these four patients had evidence of
hypercoagulability.9
APCR is also associated with early graft occlusion.
Ouriel et al. reported that 11.6% of patients had
evidence of APCR. Sixty percent (6/10) of patients
with APC-R had failed grafts compared to 24% (16/66)
in the control group.16 Patency of infrainguinal
reconstruction was 48 ^ 12% at 12 months and
33 ^ 18% at 5 years in patients with APCR compared
to 88 ^ 8% at 12 months and 71 ^ 13% at 5 years ðp ¼
0:04Þ in patients with no defect. This study noted that
patients who were positive and occluded did so
secondary to thrombosis whereas patients who were
APCR negative often had a demonstrable anatomical
lesion explaining the occlusion.
Ray et al. reported that 20% (12/60) of patients
had occluded grafts at 30 days with 11/12 having
evidence of thrombophilia defects. This study further
demonstrated that the risk of graft failure at 1 year was
65% in those with a hypercoagulable state compared to
17.9% in those with no detectable abnormality. In
addition, Lupus anticoagulant was seven times as
common in patients who had occluded grafts than in
those whose grafts remained patent. Nearly 40% of
patients in this study who had undergone a previous
revascularisation had evidence of a thrombophilia
defect compared to 27% of those with no thrombophi-
lia defect.27 In contrast, Lee et al.‘s study reported that
the presence of the antiphospholid antibodies was not
detrimental to primary 4-year patency, limb salvage or
patient survival.18
Taylor et al. tested for Antiphospholipid syndrome
and questioned patients about previous lower limb
surgical revascularisation. This investigation demon-
strated that patients with evidence of Antiphospho-
lipid syndrome were twice as likely to have had a
previous failed lower limb vascular procedure and six
times more likely to have an occlusive cause for failure
than those without.15 Mean graft patency for occluded
lower limb procedures was 17 months in patients with
APS and 50 months in those without, suggesting that
this difference in failure was not just a consequence of
duration of follow-up. However, it is known that
thrombophilia defects may be acquired after interven-
tion and therefore this may not be a true represen-
tation. Nielsen et al. reported the results of 80 patients
undergoing infra-inguinal vein bypass surgery. Nine
percent of patients had evidence of Anticardiolipin
antibodies. Graft thrombosis occurred in 57% of
patients with an Anticardiolipin antibody compared
to 30% (23/77) of those without. The overall primary
patency at 6 months was even lower with 14% in those
with Anticardiolipin antibodies compared to 57% in
those without ðp ¼ 0:03Þ:28
Sampram et al. suggested that a factor V Leiden
mutation was associated with a doubled rate of failure
for infrainguinal procedures both at 1 month and 1
year (37% vs. 22% and 46% vs. 27%) but this was
not statistically significant (p ¼ 0:15 and 0.09, respec-
tively).17
The recent publication by Curi et al. reports that
patients with hypercoagulability were more likely to
have undergone prior revascularisation than patients
deemed ‘normal’.29 The limitation of this retrospective
analysis is that only 18% of the group underwent
formal thrombophilia screening and so the normal
group might contain patients with a thrombophilia
defect and there might be an underestimation of the
prevalence of 13%. Despite this limitation the 5-year
primary patency of infrainguinal reconstructions was
poorer in those with defined hypercoagulability (28%
S. Vig et al.128
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vs. 35% p ¼ 0:004). Hypercoagulability also adversely
affected secondary patency, limb salvage and survival.
In summary patients with an identifiable thrombo-
philia defect appear to be more likely to have a failed
graft compared to patients tested as ‘normal’. The
studies suggest that the rate of occlusion maybe 2–12.5
times higher in patients with a thrombophilia defect.
Ray’s study, which carried out the most comprehen-
sive thrombophilia screen, detected a large significant
difference between the occluded and patent groups at
30-day follow-up (11/12 vs. 1/12).27 The overall wide
variation in occlusion rates associated with graft
failure is probably due to the variation in thrombo-
philia defects tested. It is not possible to conclude
which thrombophilia defect is most important from
the limited data available.
Screening
There is an increased prevalence of thrombotic defects
in patients with peripheral arterial disease. The
prevalence in young men with PAOD appears to be
15–30% and is twice that of age matched controls. In
the cohort of elderly patients with PAOD the preva-
lence still appears to be around 30–40%. Thrombo-
philia appears to increase the risk of thrombotic events
not only in the cardiac and cerebral circulation but also
following lower limb revascularisation. From the
published data available, the risk of graft failure in
patients with thrombophilia appears to be three times
more likely.
Given that over a quarter of patients presenting
with peripheral arterial disease will have thrombo-
philia and that they are at risk of interventional failure
as well as having fatal cardiac and cerebral events, it is
difficult to see why patients are not screened for
thrombophilia. It has been suggested that a full screen
should include a FBC, clotting screen, test for lupus
anticoagulant and Activated Protein C resistance in
addition to assays of Antithrombin, Protein C and free
Protein S. Genetic testing by PCR can screen for Factor
V Leiden and the prothrombin gene promoter
mutation. These tests are also expensive and may be
costed at approximately £250. There are other difficul-
ties as patients presenting with acute disease are often
treatedwith heparin or warfarin, which interferes with
many thrombophilia assays. It has also been reported
that Antithrombin, Protein C and S deficiency and
platelet hyperactivity may manifest de novo in post-
operative patients. Ray et al. showed that by the third
postoperative day 55% of patients had a thrombo-
philia abnormality, normally a low Protein C or S. At
six-month follow-up these abnormalities returned toTa
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baseline levels. This transient hypercoagulability
might be secondary to the ruptured plaque post
angioplasty or artificial graft increasing thrombogenic
potential and therefore activation of the coagulation
system.30 To date thrombophilia screening has been
very cumbersome to perform. However, the advent of
automated individual testing of thrombophilia defects
has decreased the time for a full thrombophilia test to
be reported.
Treatment Options
It is difficult to know how patients with thrombophilic
defects should be managed. One option would be to
limit the surgical options in patients who are deemed
high risk. A patient with critical ischaemia given the
knowledge that a graft was likely to fail may opt for
an ablative procedure. A claudicant with detected
thrombophilia might decide against any surgical
intervention.
It has also been difficult to define best possible
medical therapy in thrombophilic patients who may
require intervention. There are no published trials of
medical therapy in patients with thrombophilia and
PVD. Treatment of asymptomatic hypercoagulable
patients has not been routinely recommended unless
there was a strong family history of thrombosis.
Antiplatelet medication
Prophylaxis during surgery or angioplasty may be
recommended. It must be remembered that these
patients also have generalised atherosclerosis and so
there can be no justification in withholding antiplatelet
therapy, as antiplatelet agents have been shown to
reduce vascular deaths. The Antiplatelet therapy in
peripheral arterial disease consensus statement
suggests that all patients with intermittent claudica-
tion or who have had previous vascular intervention
should have long-term antiplatelet medication.31 In
addition, both the systematic overviews of the Anti-
platelet Trialists’ Collaboration and the Antithrombotic
Trialists’ Collaboration have provided unequivocal
evidence that antiplatelet therapy reduced the odds of
arterial or graft occlusion by half and overall serious
vascular events by a quarter.32,33
Ticlodipine and clopidigrel have been shown to be
more effective than aspirin in reducing overall
mortality. Both ticlodipine and clopidigrel inhibit the
Glycoprotein IIb/IIIa-receptor activation, which is the
final common pathway in platelet aggregation and
therefore thrombus formation. These drugs could
therefore have a substantial role in preventing graft
failure due to thrombus. However, there are no robust
clinical trials to date in patients undergoing peripheral
revascularisation. Ticlodipine requires haematological
monitoring as it has a 1% risk of inducing an aplastic
anaemia and, therefore, appears less desirable. How-
ever, clopidigrel has great potential, as its safety profile
appears to be better than ticlodipine and equivalent to
medium dose aspirin. The choice between the indi-
vidual drugs remains an individual decision. Medium
dose aspirin remains the most widely tested, most
convenient and least expensive antiplatelet treatment.
Anticoagulants
Heparin is used perioperatively to inhibit thrombus
formation at the site of revascularisation. It is used
widely despite the lack of good published evidence
in clinical series. The role of low molecular weight
heparin needs to be assessed in the immediate
period following revascularisation. It carries a lower
risk of bleeding, reducing the need for intensive
monitoring of coagulation and decreases the overall
costs of treatment.
The role of warfarin is controversial. At present,
many surgeons only prescribe warfarin if there is an
acute thrombosis, a failed graft requiring revascu-
larisation or a ‘gut feeling’ that a graft may fail. It is
difficult to recommend the use of warfarin routinely
in these patients without a large prospectively
randomised controlled trial because of the poten-
tially lethal side effects of bleeding. Overall, the
annual risk of bleeding on warfarin treatment is
approximately 6%, with major and fatal bleeding
events estimated to be 2% and 0.8%.34
The role of the newer Glycoprotein IIb/IIIa platelet
receptor inhibitors also needs to be carefully evalu-
ated. These drugs could potentially decrease graft
failure secondary to thrombus in hypercoagulable
patients. Whether a single infusion at the time of
surgery would be enough or whether longer treatment
with oral agents would be required needs to be
evaluated with a prospective randomised controlled
trial.
Conclusion
Optimisation of best medical practice would endea-
vour to reduce the number of failed grafts. If it is
supposed that over 40% of patients undergoing
revascularisation exhibit hypercoagulability and that
around 60% will occlude their grafts then this would
S. Vig et al.130
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account for 24 patients out of 100. Even if only a third
of these patients required re-intervention and possibly
amputation the costs are huge.
Any pharmaceutical manipulation that could posi-
tively influence the outcome of surgery in patients
with thrombophilia surely needs to be evaluated. This
can only lead to a reduction in expenditure on redo
interventions and an improvement in quality of life.
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